SAN DIEGO, March 11, 2014 /PRNewswire/ -- Suneva Medical, Inc., a privately-held aesthetics company, announced today that it has appointed Deepak Chadha to Vice President, Regulatory Affairs. With nearly two decades of regulatory experience, Chadha will be responsible for leading the development and implementation of Suneva Medical's regulatory strategies. Chadha comes to Suneva Medical after holding regulatory affairs positions at companies that include KYTHERA Biopharmaceuticals and Allergan Medical.
"Deepak has been responsible for several global regulatory strategies that have led to the successful submission and approval of aesthetic and therapeutic products in the U.S. and overseas," said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer of Suneva Medical. "This track record is highly regarded by Suneva Medical and we welcome Deepak to the team, as he will help us meet our vision to become a standout in the aesthetics market."
Chadha brings to Suneva Medical a wealth of experience in regulatory submissions and projects for drugs, biologics, medical devices and combination products. Prior to Suneva Medical, he held the role of Vice President, Regulatory Affairs at KYTHERA. During his time at KYTHERA, Chadha successfully led their lead compound ATX-101 from an early clinical phase to an NDA stage, and also supported the ex-US regulatory activities. Chadha has also served as Vice President of Global Regulatory Affairs at Allergan Medical, helping build the organization's Global Regulatory Affairs department. In addition, his career has included positions of increasing responsibility at Biomeasure Inc. (Ipsen) and Stryker Biotech.
"I am pleased to join Suneva Medical's experienced management team and am optimistic that my role will help drive the company's growth strategy," said Chadha.
For more information on Suneva Medical, visit www.sunevamedical.com.
About Suneva Medical, Inc.
Suneva Medical, Inc. is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The company currently markets ArteFill®in the U.S., Korea and Singapore; ReFissa® and Regenica® in the U.S. and Bellafill® in Canada. For more information, visit www.sunevamedical.com.
Photo - http://photos.prnewswire.com/prnh/20140311/LA81204
SOURCE Suneva Medical, Inc.